复方阿嗪米特联合莫沙必利治疗胃溃疡患者消化不良的临床观察

Clinical observation of compound azintamide joint mosapride in treatment of patients with gastric ulcer dyspepsia

目的探讨和观察复方阿嗪米特联合莫沙必利治疗胃溃疡患者消化不良的疗效。方法选择2008年1月～2009年8月本院门诊经胃镜及病理确诊的120例胃溃疡患者并分为试验组60例和对照组60例,两组病例均继续给予雷贝拉唑肠溶片10 mg bid ac、枸橼酸莫沙必利5 mg tid ac 2周治疗,试验组加服复方阿嗪米特肠溶片2粒tid pc 2周,每周复诊1次,随访2周,出现不良反应者延长随访期,直至不良反应消失。结果治疗前消化不良症状积分:试验组(23.1±2.3),对照组(24.6±1.8),两组比较差异无统计学意义(P>0.05);治疗后两组消化不良症状均有改善,症状积分均有下降,但试验组(0.8±0.3)小于对照组(1.7±0.4)(P<0.05);总有效率:试验组(94.6%),对照组(71.86%),两组比较差异有统计学意义(P<0.05);两组均无严重不良反应。结论复方阿嗪米特联合莫沙必利治疗胃溃疡患者消化不良疗效确切,值得推广和应用。

Objective To explore and observe the effect of azintamide joint mosapride in treatment of patients with gastric ulcer dyspepsia. Methods From January 2008 to August 2009, outpatients by endoscopy and pathology con- firmed 120 cases of patients with gastric ulcer patients were divided into test group of 60 patients and the control group of 60 patients, two groups of patients were continue given rabeprazole enteric-coated tablets 10 mg bid ac, cit- rate the mosapride 5 mg, tid ae 2 weeks of treatment, the experimental group plus service the compound azintamide en- teric-coated tablet the two tid pc 2 weeks, a referral 1 week 2 weeks of follow-up, adverse reactions to extend the fol- low-up period, until the adverse reactions disappear. Results Pre-treatment of dyspeptic symptoms points： test group （23.1±2.3）, control group （24.6±1.8）, the difference was not significant （P 〉 0.05）; Treatment after two groups of dyspep- tic symptoms were improved, symptom scores were decreased, but the test group （0.8±0.3） （1.7±0.4） （P 〈 0.05）; The total efficiency of the experimental group （94.6%） was higher was lower than the control group the control group （71.86%）, the difference was significant （P 〈 0.05）; The two groups had no serious adverse reactions. Conclusion Compound azin- tamide united mosapride of the treatment of patients with gastric ulcer dyspepsia, worthy of promotion and application.